Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02780401 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02780401 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 32 participants.
The verdict
NCT02780401, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of a vaccine therapy in preventing cancer from coming back in patients with non-metastatic, node positive, human epidermal growth factor receptor (HER)2 negative breast cancer in which all signs and symptoms have disappeared. Vaccines made from deoxyribonucleic acid (DNA) may help the body build an effective immune response to kill tumor cells. Giving multiple vaccinations may make a stronger immune response and prevent or delay the return of cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Sargramostim
- BIOLOGICAL pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-09-02 |
| Est. Completion | 2022-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02780401
The ClinicalTrials.gov registry entry for NCT02780401 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02780401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02780401 about?
NCT02780401 is a clinical study titled "Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission". This phase I trial studies the side effects and best dose of a vaccine therapy in preventing cancer from coming back in patients with non-metastatic, node positive, human epidermal growth factor receptor (HER)2 negative breast cancer in which all signs and symptoms have disappeared. Vaccines made fr...
What is the current status of trial NCT02780401?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-09-02. Estimated completion is 2022-10-08.
What interventions are being tested in trial NCT02780401?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Sargramostim (BIOLOGICAL), pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02780401?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.